PSYCHOPATHY.COMP Program Among Male Prison Inmates With Psychopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age19-30
SponsorUniversity of Coimbra

About this trial

The goal of this clinical trial is to learn whether PSYCHOPATHY.COMP, an individual compassion-focused, therapy-based intervention of 20 weekly sessions, can reduce psychopathy in prison inmates. Psychopathy is linked with the most severe and persistent forms of antisocial behavior. This trial will also learn whether the program improves emotional and behavioral regulation.

The main questions are:

* Does PSYCHOPATHY.COMP reduce psychopathy? * Does PSYCHOPATHY.COMP improve emotional and behavioral regulation? Researchers will compare PSYCHOPATHY.COMP with the usual individual case management support provided in prisons.

Portuguese-speaking adult male prison inmates will be invited to participate. Those who consent to participate will be screened for inclusion (T0). A total of 200 eligible participants will take part. All participants will be invited to complete a baseline assessment (T1, pre-treatment assessment), after which they will be randomly assigned to receive PSYCHOPATHY.COMP or the usual care provided in the prison for a period of around six months. All participants will be invited to complete a post-treatment assessment (T2) and a six-month follow-up assessment post-treatment. Assessments will collect data on sociodemographic characteristics and legal/criminal information, psychological outcomes (psychopathy, emotional regulation, and behavioral regulation), psychological mediators (mechanisms of change: compassion-related variables), and moderators (personality pathology), and data on social desirability.

This study aims to contribute to advancing scientific knowledge about whether and how to reduce psychopathy among prison inmates and have an impact on clinical practice and society by making available evidence-based interventions to this at-risk/high-risk population.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

male prison inmates,

Portuguese-speaking,

aged between 19 and 30 years

having at least one prior case in the juvenile justice system in which a judicial measure was applied,

Disqualifiers

suspected psychotic/autism spectrum disorders and/or cognitive impairments,

female,

sentence length inferior to 24 months since the start of the study.

Trial design

Design model

Parallel

Treatments tested in this trial

  • PSYCHOPATHY.COMP

    Behavioral

    Participants allocated to the treatment group will receive PSYCHOPATHY.COMP. PSYCHOPATHY.COMP is a manualized intervention of 20 weekly 60-min sessions (\~6 months) rooted in Compassion Focused Therapy (CFT). PSYCHOPATHY.COMP follows a progressive strategy of change in four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse and prevention. As a common feature of all therapeutic sessions, therapists are focused on developing a secure therapeutic relationship. PSYCHOPATHY.COMP is delivered by psychologists skilled in CFT (including those from prisons). Psychologists will be trained (through an intensive, face-to-face 5-day training) and supervised (one session/month) by the research team during the delivery of the intervention. During PSYCHOPATHY.COMP, participants will not receive individual therapy (psychotherapy, psychological treatment) by an accredited psychologist or therapist.

  • Treatment as Usual (TAU)

    Other intervention

    Participants in the control group will receive the routine support offered in the prison setting, tailored to individual case management and focused on behavioural management and adjustment.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: TreatmentExperimental treatment 1 intervention
Group B: ControlActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Efficacy Testing: change from eligibility assessment in participant-reported psychopathy (primary outcome) to six-month follow-up

Modified intention-to-treat (mITT, all participants randomized) and per protocol (PP, only participants who completed a sufficient dose) analyses of mean differences in participant-reported psychopathy between PSYCHOPATHY.COMP and TAU groups. Measured with the Self-Report Psychopathy Scale - Short-form (SRP-SF): a 29-item, shortened version of SRP-4 that assesses psychopathy according to the conceptualization of the Hare's Psychopathy Checklist - Revised. SRP-SF measures four facets of psychopathy: interpersonal (INT; 7 items), affective (AFF; 7 items), lifestyle (LIF; 7 items), and antisocial (ANT; 8 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Strongly disagree" to 5: "Strongly agree". Total and subscale scores are computed by summing the corresponding individual item scores (after correcting for reversed items), with higher scores indicating higher levels of psychopathic traits.

Time frame
From eligibility to six months after the end of treatment. Measured at eligibility (T0), baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
2

Efficacy Testing: change from eligibility assessment in participant-reported psychopathy (primary outcome) to six-month follow-up

mITT and PP analyses of mean differences in participant-reported psychopathy between PSYCHOPATHY.COMP and TAU groups. Measured with the Levenson Self-Report Psychopathy Scale (LSRPS): a 26-item questionnaire assessing psychopathy in two domains: primary (selfish, callous, uncaring and manipulative; 16 items) and secondary (impulsivity and behavioural control; 10 items) psychopathy, which aligns with the conceptualization of the Hare's Psychopathy Checklist - Revised. Items are rated on a four-point Likert-type scale, ranging from 1: "Strongly disagree" to 4: "Strongly agree". Total and subscale scores are computed by summing the corresponding individual item scores (after correcting for reversed items), with higher scores indicating higher levels of psychopathy.

Time frame
From eligibility to six months after the end of treatment. Measured at eligibility (T0), baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

Secondary outcomes

1

Efficacy Testing: changes from baseline in participant-reported emotional regulation (secondary outcome) to six-month follow-up

mITT and PP analyses of mean differences in emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with State-Trait Anger Expression Inventory (STAXI): 44-item self-report questionnaire assessing anger-state (how one feels in the present moment; 10 items), anger-trait (how one generally feels, 10 items; with two factors: temperament and angry reaction, 4 items each), and anger-expression (how one generally reacts or behaves when feeling enraged or angry, 24 items; three factors: anger expression-in, anger expression-out and anger control, 8 items each). Items are rated on a four-point Likert-type scale from 1: "Not at all/almost never" to 4: "Very much so/almost always". Scale scores are computed by summing item scores, higher scores indicate higher levels of anger. Anger Expression scale is calculated as the sum of Anger Expression-In and Anger Expression-Out minus Anger Control, plus a constant.

Time frame
From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
2

Efficacy Testing: changes from baseline in participant-reported emotional regulation (secondary outcome) to six-month follow-up

mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Other As Shamer Scale - 2 (OAS-2), a shorter form of the Other as Shamer scale (OAS). OAS-2 is an 8-item self-report questionnaire measuring external shame (i.e., subject's perception of being negatively judged by others). Items are rated on a five-point Likert-type scale, ranging from 0: "Never" to 4: "Almost always". The scale scores are computed by summing the corresponding individual item scores, with higher scores indicating higher levels of shame.

Time frame
From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
3

Efficacy Testing: changes from eligibility in participant-reported behavioral regulation (secondary outcome) to six-month follow-up

mITT and PP analyses of mean differences in participant-reported behavioral regulation between PSYCHOPATHY.COMP and TAU groups. Measured with an institutional behavioral grid (IBG) developed by the research team and previously used. IBG assessed the number/type of disciplinary infractions and the number of days of the punitive measures applied by the prison administration (collected from individual prison record files).

Time frame
From eligibility to six months after the end of treatment: from eligibility to baseline (T0-T1, pre-treatment), baseline to within one-month after treatment (T1-T2, during treatment), within one-month to six months after treatment (T2-T3, post-treatment)

Other outcomes

1

Mediation Testing: participant-reported compassion-related variables

mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Self-Compassion Scale (SCS): a 26-item self-report questionnaire measuring six components (subscales) of self-compassion: self-kindness (5 items), self-judgment (5 items), common humanity (4 items), isolation (4 items), mindfulness (4 items), and overidentification (4 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Almost never" to 5: "Almost always". Scores are computed by averaging item responses (after correcting for reversed items), with higher scores indicating higher levels of self-compassion.

Time frame
From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
2

Mediation Testing: participant-reported compassion-related variables

mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Compassion Scale (CS): a 16-item self-report questionnaire measuring compassion towards others, composed of subscales representing kindness (4 items), common humanity (4 items), mindfulness (4 items), and indifference (4 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Almost never" to 5: "Almost always". Scores are computed by averaging item responses (after correcting for reversed items), with higher scores indicating higher levels of compassion for others.

Time frame
From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
3

Mediation Testing: participant-reported compassion-related variables

mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Fears of Compassion Scales (FCS): a 38-item self-report questionnaire that comprises three scales measuring: Fears of expressing compassion for others (10 items); Fears of receiving compassion from others (13 items), and Fears of compassion for self (15 items). Items are rated on a five-point Likert-type scale from 0 "Don't agree at all" to 4: "Completely agree". Scores are computed by averaging item responses, with higher scores indicating greater fears of compassion in the respective dimension.

Time frame
From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment
4

Moderation Testing: participant-reported personality pathology pre-treatment

mITT and PP analyses of mean differences in personality pathology between PSYCHOPATHY.COMP and TAU groups. Measured with the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II): a semi-structured diagnostic interview assessing Axis II personality disorders from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), and the depressive and passive-aggressive personality disorders (included in DSM-IV's appendix). It can be used to diagnose personality disorders categorically (present/absent) and dimensionally (according to the number of criteria met for each diagnosis) and is considered the "gold standard" for Personality Disorders diagnosis. The SCID-II also provides a summary with a pathology profile of scores over the assessed Personality Disorders.

Time frame
Antisocial Personality Disorder (ASPD) measured at eligibility (T0, pre-treatment) and the other personality diagnosis at baseline assessment (T1, pre-treatment)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Coimbra

Lead sponsor

European Regional Development Fund

Collaborator

Portuguese National Funding Agency for Science, Research and Technology (FCT)

Collaborator